Cross-reactive antibody response to mRNA SARS-CoV-2 vaccine after recent COVID-19-specific monoclonal antibody therapy
Abstract Efficacy of COVID-19 vaccines administered after COVID-19-specific monoclonal antibody is unknown, and ‘antibody interference’ might hinder immune responses leading to vaccine failure. In an IRB-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar post-vaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD), for four important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351 and P.1), as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.
